抗寨卡病毒药物研究进展  

Research progress on anti-Zika drugs

作　　者：董卓凡 韩尧 孙岩松 杨海燕[1] 李浩 DONG Zhuofan;HAN Yao;SUN Yansong;YANG Haiyan;LI Hao(College of Public Health,Zhengzhou University,Zhengzhou 450001,China;Institute Microbiology and Epidemiology,Academy Medical Sciences)

机构地区：[1]郑州大学公共卫生学院,河南郑州450001 [2]军事医学研究院微生物流行病研究所

出　　处：《中国病原生物学杂志》2024年第5期619-620,F0003,F0004,共4页Journal of Pathogen Biology

基　　金：国家自然科学基金青年科学基金项目(No.2022BCA018)。

摘　　要：寨卡病毒(Zika virus,ZIKV)是黄病毒科家族中的一员,已成为世界范围内威胁人类健康的潜在病毒。寨卡病毒感染后主要表现为皮疹、发热和关节痛等非特异性症状,但有时也会导致严重的神经系统并发症,例如格林-巴利综合征和新生儿小头畸形。目前,还没有FDA批准的疫苗或药物,因此,迫切需要开安全有效的药物用于控制寨卡病毒的感染。在本文中,我们系统分析了ZIKV药物研发的进展,包括临床批准药物的再利用,抑制剂的筛选、病毒蛋白靶向药物的发现以及小核酸药物的应用。本综述旨在为寨卡病毒感染的预防和治疗提供新的参考。The Zika virus(ZIKV),a member of the Flaviviridae family,has become a potential virus threatening human health worldwide.Although the primary manifestations of Zika virus infection are non-specific symptoms such as rash,fever,and joint pain,it can sometimes lead to severe neurological complications,such as Guillain-Barre syndrome and microcephaly in newborns.Currently,there are no FDA-approved vaccines or drugs available for ZIKV.And there is an urgent need to prescribe safe and effective drugs to control Zika virus infection.Inthisreview,we systematically summarize the overall strategy for the discovery of ZIKV drugs,which encompasses the repurposing of clinically approved drugs,screening for virus entry inhibitors,the discovery of virus protein-targeted drugs,and the application of small nucleic acid drugs.The review aims to provide new ideas and research directions for the treatment and prevention of Zika virus infection.

关 键 词：寨卡病毒 抗病毒药物 抑制剂 CRISPR 综述 

分 类 号：R978.7[医药卫生—药品]